|
MADISON, WI—December 2, 2005—NimbleGen Systems Inc. announced today it has raised
$8.2 million in a private venture financing round led by Cargill Ventures and Skyline Ventures.
NimbleGen, the leading provider of flexible high-density microarray products and services for
genetic analysis, has raised a total of $50 million since its inception in 1999. The company will
use the new funding to finance its rapid expansion as it works to enable High-Definition
GenomicsSM, which provides researchers enhanced detail of information concerning genetic
variation, and clarity of complex data sets.
"NimbleGen is uniquely positioned in the microarray market,” said Jim Sayre, president of Cargill
Ventures. “The company has made enormous strides in the past year, becoming the ChIP-chip
market leader, launching its CGH platform with the highest resolution in the market, and pushing
the frontier of emerging, novel applications."
Dr. David Lowe, NimbleGen Director at Skyline Ventures, agreed, “We’re confident in
NimbleGen’s technology and management. NimbleGen Systems has assembled a world class
team of managers and scientists who have done an outstanding job of positioning the company
for rapid growth with their technical accomplishments and strategic relationships, serving
customers’ needs in new and existing markets.”
“The additional funds support NimbleGen’s rapid pace of growth,” said NimbleGen President and
CEO Dr. Stanley Rose. “We are extremely excited about the opportunity to develop and leverage
leading positions in a variety of emerging markets involving genetic analysis. We have been
growing very rapidly over the past two quarters, and our investors have stepped forward to
provide the resources needed to take NimbleGen to the next level of commercial success.”
NimbleGen is working to enable High-Definition Genomics, a rapidly growing approach to
genomic science that provides enhanced detail of information concerning genetic variation, and
clarity of complex data sets. The flexibility of NimbleGen’s microarray platform combined with its
proven products of expression, ChIP-chip, CGH, and comparative genome sequencing provide
the basis for new avenues of basic genomics research as well as diagnostics and therapeutic
development.
All of the company’s existing venture capital and institutional investors participated in the round,
including Cargill Ventures, Skyline Ventures, Baird Venture Partners, the State of Wisconsin
Investment Board, Tactics II Investments LLC, Topspin Partners, Venture Investors LLC, and The
Wisconsin Alumni Research Foundation (WARF).
________________________
NimbleGen Systems Inc.
NimbleGen Systems, the leading supplier of flexible high-density microarray products and services, is
enabling a new era of "High- Definition Genomics." NimbleGen uniquely produces high-density arrays of
isothermal long oligos that provide superior results for advanced genomic analysis methods such as CGH,
ChIP, microbial whole-genome resequencing and expression tiling. NimbleGen's High-Definition Genomics
enables scientists to obtain and integrate complex genetic data sets not previously accessible, providing a
much clearer understanding of genomics and systems biology. This improved performance is made possible
by NimbleGen's Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid,
high-yield photochemistry to synthesize DNA.
|
